Journal of Clinical Oncology
Articles in this Issue
Implementation of a remote patient monitoring system by electronic patient-reported outcomes (ePROs) in neuro-oncology based on real-world data in France and Belgium.
e13885 Background: Remote patient monitoring (RPM) using electronic Patient Reported Outcomes (ePROs) offers a unique opportunity to detect actionable sym...
Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET amplification or overexpression after failure on EGFR-TKI treatment: A phase Ib/II study.
8632 Background: MET amplification (METamp) or overexpression (METov) is the most common “off-target” mechanism that drive...
The IRAK4 long isoform as widely upregulated in non-splicesome mutated acute myeloid leukemia and as altered by hypomethylating agent therapy.
6524 Background: IRAK4, a kinase effector of MyD88 signaling downstream of Toll-Like Receptor and IL-1 receptor pathways, has recently been shown to funct...
An open-label, dose-finding, phase Ib study to assess the safety, tolerability of nesuparib (JPI-547), a dual inhibitor of PARP/TNKS, in combination with modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine-nab-paclitaxel (GemAbraxane) in patients with locally advanced and metastatic pancreatic cancer.
TPS4227 Background: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths, with most cases diagnosed at advanced stages. Current mai...
Achieving equity in genomic testing for breast cancer through partner-led strategies and policies.
11027 Background: Genomic testing is recommended for individuals with estrogen/progesterone receptor-positive, HER2-negative early-stage breast cancer to...
Retinoblastoma patient outcomes in the contemporary era: The RIVERBOAT Consortium.
10062 Background: Retinoblastoma (RB) is the most common childhood eye tumor. Intraocular RB cure rates approach 100%. Therefore, treatment now focuses on...
Tumor type prediction via tissue- and liquid-based comprehensive genomic profiling: High-specificity tobacco signature detection to support lung cancer diagnosis.
8036 Background: Cigarette smoking exposes the lungs to tobacco mutagens, producing a distinct mutational pattern with elevated tumor mutational burden an...
Survival outcomes and prognostic factors in marginal zone lymphoma: A single-center experience from India.
e19063 Background: Marginal Zone Lymphoma (MZL) is a rare subtype of Non-Hodgkin Lymphoma, accounting for only 5–12% of all B-cell lymphomas. There is lim...
Genomic alterations in metastatic renal cell carcinoma (RCC): Impact on prognosis and response to frontline therapy.
e16529 Background: Genomic alterations can serve as prognostic and predictive biomarkers for many malignancies. We report a large dataset to describe the...
Exploring nationwide trends in multiple myeloma (MM), autologous stem cell transplants (ASCTs), chimeric antigen receptor T-cell (CAR-T) therapy and coronavirus disease 2019 (COVID-19) in hospitalizations from 2017 to 2021.
e19539 Background: MM represents approximately 17% of hematologic malignancies. Several new MM treatments have been approved over the years. This study ex...
Characterizing unmet supportive care needs in diverse adolescent and young adult cancer survivors.
11104 Background: Research addressing the supportive care needs of diverse adolescent and young adult (AYA) cancer survivors remains underdeveloped relati...
Predicting valvular heart disease in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime Cohort (SJLIFE).
10070 Background: Radiotherapy (RT)-related valvular heart disease (VHD) is an understudied late toxicity of childhood cancer therapy. We aimed to define...
Efficacy and manageable toxicity of mogamulizumab in a real-world North American cohort of adult T-cell leukemia/lymphoma (ATLL).
e18603 Background: Adult T-cell leukemia/lymphoma (ATLL), a malignancy of CD4+ T-cells linked to HTLV-1 infection, carries a poor prognosis. Treatment opt...
Baseline circulating growth differentiation factor-15 and the cancer phenotype in the PROACC-1 phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia.
12060 Background: Growth differentiation factor-15 (GDF-15) is an emerging therapeutic target in cancer cachexia. However, the association of circulating...
Evaluating AI-driven auditing of mammography reports for BI-RADS compliance.
e13720 Background: The Breast Imaging Reporting and Data System (BI-RADS) provides standardized guidelines for accurate reporting of mammograms which is e...
Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort.
1030 Background: T-DXd is the standard second-line treatment for HER2-positive MBC with TTC being the preferred third-line option. However, the efficacy o...
Impact of incretin mimetic therapy on weight change in patients with cancer: A pan-cancer analysis from a single institutional cohort.
10598 Background: An elevated body mass index (BMI) is a frequent comorbidity in patients with cancer. Chemotherapy can exacerbate metabolic dysfunction a...
A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases.
1018 Background: Brain metastases (BMs) of triple-negative breast cancer (TNBC) is a lethal disease often associated with a limited life span of approxima...
Cardiovascular toxicity of fruquintinib in patients with colorectal and other cancers: A systematic review and meta-analysis.
e15520 Background: Fruquintinib is a highly selective tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, an...
Real-world study of anti–PD-1 combined with regorafenib and raltitrexed as third-line therapy in colorectal cancer.
e15510 Background: Thisstudy aimed to assess the effectiveness of combining the anti-PD-1 drug with regorafenib and raltitrexed as a third-line treatment...
Results of a phase I clinical trial of cetuximab biosimilar (RPH-002).
e18036 Background: Hyperexpression of the human epidermal growth factor receptor (EGFR) is observed in a number of cancers, including head and neck cancer...
Intra/intertumoral heterogeneity assessed by blood-based next generation sequencing (NGS) to predict inferior survival outcome compared to intratumoral heterogeneity assessed by tissue-based NGS in advanced stage non-small cell lung cancer (NSCLC).
e20550 Background: Intratumoral heterogeneity (ITH) refers to the presence of multiple, genetically diverse cell subpopulations within a single tumor. Whi...
Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab/relatlimab.
e14001 Background: Patients with melanoma brain metastases (MBM) have a poor prognosis. Immune checkpoint inhibitors (ICI) have improved the prognosis of...
New diagnostic technology for the isolation and analysis of live myeloma cells from the blood of multiple myeloma patients.
e14543 Background: Multiple myeloma (MM) is a plasma cell malignancy in which plasma cells proliferate in bone marrow (BM), so BM examination is essential...
Comparative analysis of the anti-tumor activity and mechanism of action of TARA-002 and BCG in bladder cancer models.
e16613 Background: Intravesical instillations of Bacillus Calmette-Guérin (BCG) is the current standard of care for high-risk Non-Muscle Invasive Bladder...